Connect your AI

GRAIL, Inc. GRAL Cash Cash Equivalents And Short Term Investments

Cash Cash Equivalents And Short Term Investments at other companies

Tango TherapeuticsTNGX

——

PrecigenPGEN

——

Jazz PharmaceuticalsJAZZ

——

Other financials

Income statement

Revenue$40.8M+28.1%

Operating income-$135.8M+11.6%

Net income-$93.2M+12.3%

EPS (diluted)-$2.29+26.1%

Balance sheet

Cash & equivalents$76.3M-44.4%

Total debt$51.0M-20.7%

Total equity$2.5B+3.6%

Total assets$2.8B-1.5%

Cash flow

Operating cash flow-$87.0M+8.4%

CapEx$503.0K+711%

Free cash flow-$87.5M+8.0%

Valuation

Market cap$2.62B+145%

Enterprise value$2.6B+164%

P/S16.8×+8.6×

Profitability

Operating margin-348.7%-153pp

Net margin-253.2%-115pp

FCF margin-187.2%-60.4pp

Returns & leverage

Return on equity-16.1%—

Debt / equity0×0.0×

Current ratio11.7×+2.0×

Where this comes from

Reported directly by GRAIL, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsAndShortTermInvestments.

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s cash cash equivalents and short term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is GRAIL, Inc.'s cash cash equivalents and short term investments?: GRAIL, Inc. (GRAL) reported cash cash equivalents and short term investments of $820.31M in Q1 2026.
How has GRAIL, Inc.'s cash cash equivalents and short term investments changed year-over-year?: GRAIL, Inc.'s cash cash equivalents and short term investments increased by 22.0% year-over-year, from $672.6M to $820.31M.